Acc Releases Consensus Decision Pathway For Cvd Risk Reduction In T2d And Ascvd | Latest News RSS feed

Acc Releases Consensus Decision Pathway For Cvd Risk Reduction In T2d And Ascvd - Latest News


Expert Consensus Decision Pathway Addresses Changing Paradigm in Managing T2D Patients With ASCVD

The ACC's 2018 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with ... 1Ras in the treatment of patients with T2D and atherosclerotic cardiovascular ... read more

ACC Pathway Finds Empagliflozin "Preferred" SGLT2 Therapy for Patients With Type 2 Diabetes, ASCVD

The authors noted that until recently, medications to control blood glucose were not expected to offer any benefit in helping patients avoid cardiovascular events. A new American College of Cardiology ... read more

Clear Consensus—Treat Cardiovascular Disease Concurrent with Diabetes

1 The American College of Cardiology issued an expert consensus statement—the Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with T2D and ASCVD ... ... read more

Looking for another news?


Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

benefit and should be used for reducing CV risk in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), according to a report of the American College of Cardiology ... read more


The Cholesterol Dilemma: Treating the Risk or Treating to LDL-C Goal?

For those with ASCVD risk < 7.5% who do not achieve 30% to < 50% LDL-C reduction ... reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–1509. 14. Lloyd-Jones DM, et al. 2016 ... read more

Relationship Between Heart Failure and Diabetes Seen Throughout ACC Sessions

Driving this is the ACC’s new Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type ... and that people with diagnosed T2D account for more than ... read more

US Lipid Guidelines Revisited: Any Regrets?

Many things go into that decision ... a 50% reduction. Is that within about 4-6 weeks of treatment? Dr Lloyd-Jones: For these higher-risk patients, who are secondary prevention patients because they ... read more

Statin Therapy in Patients with Diabetes

5 The combination of simvastatin and ezetimibe resulted in a significantly lower risk of cardiovascular events than that of simvastatin mono-therapy for post-ACS patients who are 50 or older. The ... read more

Young Investigators Awards

This is also the opportunity to award two young investigators (under 36 ... in patients with CAD and concomitant T2D as well as in human aortic endothelial cells (HAEC). As cardiovascular risk ... read more

Hyperlipidemia: Drugs for Cardiovascular Risk Reduction in Adults

ACC/AHA ... cardiovascular risk in adults.1 This guideline presented significant changes to previous recommendations on the management of hyperlipidemia for primary and secondary prevention of ... read more

Managing Dyslipidemia to Reduce Cardiovascular Risk in Adults With Diabetes

8,9 Statins are critical for lowering LDL-C in adults with diabetes and those without diabetes who are at high risk or established atherosclerotic cardiovascular disease (ASCVD ... update of the 2016 ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us